{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T09:59:32Z","timestamp":1785059972302,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejca.2023.02.011","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T03:38:42Z","timestamp":1676432322000},"page":"30-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck"],"prefix":"10.1016","volume":"184","author":[{"given":"Akihisa","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6639-9753","authenticated-orcid":false,"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-1001","authenticated-orcid":false,"given":"Yuri","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1336-1329","authenticated-orcid":false,"given":"Nobukazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":false,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2023.02.011_bib1","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.011_bib2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00280-014-2459-z","article-title":"An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck","volume":"73","author":"Saloura","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"10.1016\/j.ejca.2023.02.011_bib3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10167","key":"10.1016\/j.ejca.2023.02.011_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejca.2023.02.011_bib5","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1158\/1078-0432.CCR-18-3944","article-title":"Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use","volume":"25","author":"Ferris","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6371","key":"10.1016\/j.ejca.2023.02.011_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.011_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.011_bib8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.ejca.2023.02.011_bib9","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2023.02.011_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.lungcan.2017.07.034","article-title":"Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"112","author":"Schvartsman","year":"2017","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2023.02.011_bib11","doi-asserted-by":"crossref","first-page":"e1018","DOI":"10.1002\/onco.13754","article-title":"Safety and efficacy of cetuximab-based salvage chemotherapy after checkpoint inhibitors in head and neck cancer","volume":"26","author":"Cabezas-Camarero","year":"2021","journal-title":"Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2023.02.011_bib12","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1200\/JCO.2020.38.15_suppl.6505","article-title":"KEYNOTE-048: progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)","volume":"38","author":"Harrington","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.02.011_bib13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2023.02.011_bib14","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1200\/JCO.2020.38.15_suppl.6509","article-title":"Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcinoma (R\/M HNSCC) treated with immune checkpoint inhibitors (ICIs)","volume":"38","author":"Vellanki","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6371","key":"10.1016\/j.ejca.2023.02.011_bib15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ejca.2023.02.011_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.02.011_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105380","article-title":"Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival","volume":"119","author":"Lien","year":"2021","journal-title":"Oral Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.011_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96538-7","article-title":"Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab","volume":"11","author":"Minohara","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.ejca.2023.02.011_bib19","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.21873\/anticanres.14532","article-title":"Salvage chemotherapy after nivolumab for recurrent or metastatic head and neck carcinoma","volume":"40","author":"Fushimi","year":"2020","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2023.02.011_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cas.14706","article-title":"Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab","volume":"112","author":"Nishikawa","year":"2021","journal-title":"Cancer Sci"},{"issue":"10212","key":"10.1016\/j.ejca.2023.02.011_bib21","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2023.02.011_bib22","first-page":"3285","article-title":"Outpatient oral chemotherapy with S-1 for unresectable or distant metastatic head and neck cancer","volume":"33","author":"Maeda","year":"2013","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2023.02.011_bib23","first-page":"577","article-title":"Outpatient chemotherapy with S-1 for recurrent head and neck cancer","volume":"29","author":"Yamashita","year":"2009","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.ejca.2023.02.011_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10156-009-0712-x","article-title":"Safety and efficacy of S-1 chemotherapy in recurrent\/metastatic head and neck cancer","volume":"15","author":"Suzuki","year":"2009","journal-title":"J Infect Chemother"},{"issue":"28","key":"10.1016\/j.ejca.2023.02.011_bib25","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:34Z","timestamp":1760733574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":25,"alternative-id":["S0959804923000886"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}